---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-055070"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2026-05-12T20:10:33+00:00"
generated_at: "2026-05-12T21:00:01.514403+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD Q1 2026 net income $103K, license revenue up 84% YoY

## Summary
- Net income from continuing operations of $103K vs net loss of $636K in Q1 2025.
- License revenue $724K, up 84% YoY, primarily from Mayne License Agreement.
- Total operating expenses $1.45M, down 13.6% from $1.67M in prior year.
- Cash and cash equivalents $8.4M as of March 31, 2026.
- Company continues to evaluate strategic alternatives including M&A or sale of assets.

## SEC filing metadata
- accession: 0001213900-26-055070
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2026-05-12T20:10:33+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000121390026055070/0001213900-26-055070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000121390026055070/ea0289776-8k_therapeu.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-055070
- JSON: https://secwatch.observer/filing/0001213900-26-055070.json
- Plain text: https://secwatch.observer/filing/0001213900-26-055070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.